Oncolytics Biotech® Highlights Key Developments and Future Studies in Cancer Treatments

2 min read | October 04, 2024 05:57 AM PDT | By Team Kalkine Media

Google News:

Oncolytics Biotech® Highlights Key Developments and Future Studies in Cancer Treatments — Image source: Shutterstock

Recent News

Oracle's AI Push Gains Ground Across Critical Services

Why is Marathon Petroleum (NYSE:MPC) moving with S&P 500 Energy?

Why AbbVie (NYSE:ABBV) Gains in S&P 500 Index Biopharma Push?

Why FactSet Research Systems Anchors Index Stability Gains Now?

Make Kalkine Media
My Trusted Source

Highlights:

Oncolytics Biotech reports a median progression-free survival benefit of 5.7 months in the BRACELET-1 trial for HR+/HER2- breast cancer.
A Phase 2 study aimed at FDA accelerated approval is set to commence in the first half of 2025, focusing on 180 patients with advanced or metastatic breast cancer.
Strategic collaborations with GCAR and PanCAN will enhance research efforts in pancreatic cancer, with initial efficacy results from the GOBLET study anticipated in the second half of 2025.

Oncolytics Biotech {NASDAQ:ONCY} has announced noteworthy advancements in the treatment of breast and pancreatic cancers, marking significant progress in its clinical research initiatives. The results from the BRACELET-1 trial in HR+/HER2- breast cancer indicate a median progression-free survival (PFS) benefit of 5.7 months for the cohort receiving the combination of pelareorep and paclitaxel, compared to those treated with standard chemotherapy alone. These promising findings pave the way for a forthcoming Phase 2 study, which aims to secure FDA accelerated approval. This study is scheduled to begin in the first half of 2025 and will involve 180 patients diagnosed with advanced or metastatic breast cancer.

In addition to its focus on breast cancer, Oncolytics Biotech is actively advancing studies related to gastrointestinal cancers. The company has identified several key milestones projected for 2025, highlighting its commitment to expanding its research portfolio in this critical area. Collaborations with the Global Coalition for Adaptive Research (GCAR) and the Pancreatic Cancer Action Network (PanCAN) are set to bolster research efforts specifically targeting pancreatic cancer, a disease notorious for its challenging prognosis.

The GOBLET study, which focuses on pancreatic cancer, aims to provide initial efficacy results that are anticipated in the second half of 2025. These collaborative research efforts underscore Oncolytics Biotech's dedication to exploring novel therapeutic options for patients facing this aggressive form of cancer.

Through these initiatives, Oncolytics Biotech demonstrates a robust commitment to advancing treatment modalities that could significantly enhance patient outcomes in both breast and pancreatic cancers. The company’s focus on innovative therapies, supported by promising trial results and strategic partnerships, reinforces its position as a key player in the evolving landscape of cancer treatment.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.